MEDP
Medpace Holdings, Inc.
$470.70
+0.84%
$13.3B
No data for this timeframe.
Vol
Market Cap$13.3B
Cap SizeLarge Cap
Analyst ConsensusHold (45%)
Inst. Holders10 funds
Inst. Value$2.5B
Inst. Activity2 buys / 2 sells
Insider Activity0B / 2S
Insider Net $-$21.8M
SEC Reports3
Congressional4 trades
Exchange Nasdaq·Sector Services-Commercial Physical & Biological Research·Inc. DE·CIK 0001668397·Prev Close $466.79
Recent Activity
Jun 8, 2026
SEC
Medpace, Inc. obtained a default judgment against Agenus Inc. and Garo H. Armen in a breach-of-contract and breach-of-fi
COURT-RULING — Impact 5/10
May 28, 2026
Insider
EWALD STEPHEN P sold 16,349 shares
General Counsel & Corp. Secy. @ $138.87 ($2.3M)
May 28, 2026
Insider
EWALD STEPHEN P sold 16,349 shares
General Counsel & Corp. Secy. @ $450.00 ($7.4M)
May 28, 2026
Insider
EWALD STEPHEN P sold 16,349 shares
General Counsel & Corp. Secy. @ $0.00 ($0.00)
May 18, 2026
dark_pool
Dark Pool: MEDP — 0.6M shares, 27,512 trades
Week starting 2026-05-18. Total ATS volume: 553,061 shares across 27,512 trades.
May 15, 2026
Congress
David Taylor buy
$1,001 - $15,000 — House
Apr 22, 2026
SEC
Medpace reported strong Q1 2026 earnings with revenue up 26.5% YoY and EPS of $4.28, beating consensus. However, Preside
8-K — Impact 6/10
Apr 1, 2026
SEC
Analysis based on filing metadata only — document content was unavailable
DEFA14A — Impact 3/10
Price Targets
$442.83
-5.9% upside
Sell
Current $470.70
Low $329.00
Median $456.00
High $495.00
12 analysts
$329.00
$495.00
Analyst Ratings
4Strong Buy
5Buy
10Hold
1Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 24, 2026 | Barclays | MAINTAIN | Equal-Weight → Equal-Weight |
| Apr 24, 2026 | BMO Capital | MAINTAIN | Market Perform → Market Perform |
| Apr 24, 2026 | RBC Capital | MAINTAIN | Outperform → Outperform |
| Apr 24, 2026 | Baird | MAINTAIN | Outperform → Outperform |
| Mar 6, 2026 | Barclays | UPGRADE | Underweight → Equal-Weight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $3.96 ▼ -3.0% | $3.71 — $4.11 | 28% YoY | 8 |
| Next Q | $4.26 ▼ -5.2% | $4.06 — $4.43 | 10% YoY | 8 |
| Current FY | $17.06 | $16.70 — $17.78 | 12% YoY | 10 |
| Next FY | $18.56 | $17.85 — $19.26 | 9% YoY | 10 |
Latest Reports
BULLISH
COURT-RULING
5/10
Medpace, Inc. obtained a default judgment against Agenus Inc. and Garo H. Armen in a breach-of-contract and breach-of-fi
Jun 8, 2026
MIXED
8-K
6/10
Medpace reported strong Q1 2026 earnings with revenue up 26.5% YoY and EPS of $4.28, beating consensus. However, Preside
Apr 22, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $1.3B | — |
| RENAISSANCE TECHNOLOGIES LLC | $261.7M | TRIM |
| MORGAN STANLEY | $234.0M | ADD |
| Mawer Investment Management Ltd. | $228.8M | TRIM |
| BANK OF AMERICA CORP | $118.3M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 28, 2026 | EWALD STEPHEN | M | $2.3M |
| May 28, 2026 | EWALD STEPHEN | SELL | $7.4M |
| May 28, 2026 | EWALD STEPHEN | M | $0.00 |
| May 15, 2026 | Carley Brian | A | $0.00 |
| May 15, 2026 | DAVENPORT FRED | A | $0.00 |
Congressional Trades
2 members: 3 buys, 1 sells
| Member | Party | Type | Amount |
|---|---|---|---|
| David Taylor | R | BUY | $1,001 - $15,000 |
| David Taylor | R | BUY | $1,001 - $15,000 |
| David Taylor | R | BUY | $1,001 - $15,000 |
10 institutional holders with $2.5B total value (4,439,961 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, MORGAN.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 2,261,848 | $1.3B | 50.9% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 465,908 | $261.7M | 10.5% | TRIM -27.2% |
| 3 | MORGAN STANLEY | 416,678 | $234.0M | 9.4% | ADD +62.8% |
| 4 | Mawer Investment Management Ltd. | 407,302 | $228.8M | 9.2% | TRIM -37.0% |
| 5 | BANK OF AMERICA CORP /DE/ | 210,696 | $118.3M | 4.7% | — |
| 6 | FMR LLC | 203,721 | $114.4M | 4.6% | DOUBLED +2507.1% |
| 7 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 189,787 | $106.6M | 4.3% | NEW |
| 8 | NORGES BANK | 181,886 | $102.2M | 4.1% | NEW |
| 9 | TWO SIGMA INVESTMENTS, LP | 57,381 | $32.2M | 1.3% | TRIM -32.8% |
| 10 | WELLS FARGO & COMPANY/MN | 44,754 | $25.1M | 1.0% | ADD +52.3% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Mawer Investment Management Ltd. | TRIM | 646,774 | 407,302 | -37.0% | $228.8M | 2025-Q4 |
| FMR LLC | DOUBLED | 7,814 | 203,721 | +2507.1% | $114.4M | 2025-Q4 |
| NORGES BANK | NEW | — | 181,886 | — | $102.2M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 85,369 | 57,381 | -32.8% | $32.2M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 678,088 | 493,588 | -27.2% | $253.8M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 266,750 | 85,369 | -68.0% | $43.9M | 2025-Q3 |
| FMR LLC | TRIM | 26,947 | 7,814 | -71.0% | $4.0M | 2025-Q3 |
| NORGES BANK | EXIT | 212,188 | 0 | -100.0% | $0.00 | 2025-Q3 |
| MORGAN STANLEY | ADD | 299,806 | 488,227 | +62.8% | $153.2M | 2025-Q2 |
| UBS Group AG | ADD | 186,471 | 273,682 | +46.8% | $85.9M | 2025-Q2 |
| NORGES BANK | NEW | — | 212,188 | — | $66.6M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | ADD | 34,776 | 52,951 | +52.3% | $16.6M | 2025-Q2 |
| FMR LLC | TRIM | 48,270 | 26,947 | -44.2% | $8.5M | 2025-Q2 |
| Mawer Investment Management Ltd. | NEW | — | 696,219 | — | $212.1M | 2025-Q1 |
| MORGAN STANLEY | ADD | 237,467 | 299,806 | +26.3% | $91.3M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | ADD | 154,505 | 234,905 | +52.0% | $71.6M | 2025-Q1 |
| FMR LLC | TRIM | 112,223 | 48,270 | -57.0% | $14.7M | 2025-Q1 |
| NORGES BANK | EXIT | 210,272 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS Group AG | DOUBLED | 61,951 | 160,344 | +158.8% | $53.3M | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 198,904 | — | $66.4M | 2024-Q3 |
11 unique insiders with 2 transactions. Net insider value: -$21.8M ($0.00 bought, $21.8M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 28, 2026 | EWALD STEPHEN P | General Counsel & Corp. Secy. | M | 16,349 | $138.87 | $2.3M |
| May 28, 2026 | EWALD STEPHEN P | General Counsel & Corp. Secy. | SELL | 16,349 | $450.00 | $7.4M |
| May 28, 2026 | EWALD STEPHEN P | General Counsel & Corp. Secy. | M | 16,349 | $0.00 | $0.00 |
| May 15, 2026 | Carley Brian T | Director | A | 1,110 | $0.00 | $0.00 |
| May 15, 2026 | DAVENPORT FRED B JR | Director | A | 1,110 | $0.00 | $0.00 |
| May 15, 2026 | Gwadry-Sridhar Femida H. | Director | A | 1,110 | $0.00 | $0.00 |
| May 15, 2026 | Kraft Robert O. | Director | A | 1,110 | $0.00 | $0.00 |
| May 15, 2026 | McCarthy Cornelius P. III | Director | A | 1,110 | $0.00 | $0.00 |
| May 15, 2026 | Zander Dani S. | Director | A | 1,110 | $0.00 | $0.00 |
| Apr 24, 2026 | Brady Kevin M. | CFO & Treasurer | M | 7,000 | $138.87 | $972.1K |
| Apr 24, 2026 | Brady Kevin M. | CFO & Treasurer | M | 7,000 | $0.00 | $0.00 |
| Apr 24, 2026 | Brady Kevin M. | CFO & Treasurer | A | 10,000 | $0.00 | $0.00 |
| Apr 24, 2026 | Brady Kevin M. | CFO & Treasurer | A | 5,000 | $0.00 | $0.00 |
| Apr 24, 2026 | BURWIG SUSAN E | Exec. VP, Operations | A | 10,000 | $0.00 | $0.00 |
| Apr 24, 2026 | BURWIG SUSAN E | Exec. VP, Operations | A | 5,000 | $0.00 | $0.00 |
| Apr 24, 2026 | EWALD STEPHEN P | General Counsel & Corp. Secy. | M | 3,500 | $138.87 | $486.0K |
| Apr 24, 2026 | EWALD STEPHEN P | General Counsel & Corp. Secy. | M | 3,500 | $0.00 | $0.00 |
| Apr 24, 2026 | EWALD STEPHEN P | General Counsel & Corp. Secy. | A | 10,000 | $0.00 | $0.00 |
| Apr 24, 2026 | EWALD STEPHEN P | General Counsel & Corp. Secy. | A | 5,000 | $0.00 | $0.00 |
| Apr 24, 2026 | Troendle August J. | CEO | A | 20,000 | $0.00 | $0.00 |
| Apr 24, 2026 | Troendle August J. | CEO | A | 10,000 | $0.00 | $0.00 |
| Mar 31, 2026 | Carley Brian T | Director | M | 36 | $0.00 | $0.00 |
| Mar 31, 2026 | Carley Brian T | Director | M | 36 | $0.00 | $0.00 |
| Mar 31, 2026 | Kraft Robert O. | Director | M | 33 | $0.00 | $0.00 |
| Mar 31, 2026 | Kraft Robert O. | Director | M | 33 | $0.00 | $0.00 |
| Mar 31, 2026 | McCarthy Cornelius P. III | Director | M | 29 | $0.00 | $0.00 |
| Mar 31, 2026 | McCarthy Cornelius P. III | Director | M | 29 | $0.00 | $0.00 |
| Mar 18, 2026 | BURWIG SUSAN E | Exec. VP, Operations | M | 12,000 | $0.00 | $0.00 |
| Mar 18, 2026 | BURWIG SUSAN E | Exec. VP, Operations | M | 12,000 | $166.73 | $2.0M |
| Mar 17, 2026 | GEIGER JESSE J | President | SELL | 31,707 | $455.30 | $14.4M |
| Mar 17, 2026 | GEIGER JESSE J | President | M | 31,707 | $138.87 | $4.4M |
| Mar 17, 2026 | GEIGER JESSE J | President | M | 31,707 | $0.00 | $0.00 |
| Feb 13, 2026 | BURWIG SUSAN E | Exec. VP, Operations | M | 10,984 | $0.00 | $0.00 |
| Feb 13, 2026 | Carley Brian T | Director | M | 6,472 | $54.99 | $355.9K |
| Feb 13, 2026 | Carley Brian T | Director | M | 6,472 | $0.00 | $0.00 |
| Feb 13, 2026 | BURWIG SUSAN E | Exec. VP, Operations | M | 10,984 | $107.93 | $1.2M |
3 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 1 mixed, 1 neutral. Avg impact: 4.7/10.
BULLISH
COURT-RULING
5/10
Medpace, Inc. obtained a default judgment against Agenus Inc. and Garo H. Armen in a breach-of-contr
Jun 8, 2026
MIXED
8-K
6/10
Medpace reported strong Q1 2026 earnings with revenue up 26.5% YoY and EPS of $4.28, beating consens
Apr 22, 2026
NEUTRAL
DEFA14A
3/10
Analysis based on filing metadata only — document content was unavailable
Apr 1, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Hold (45% buy). Based on 20 analysts: 4 strong buy, 5 buy, 10 hold, 1 sell, 0 strong sell.
Analyst Price Targets
$442.83 mean target
-5.9% upside
Sell (2.62)
$329.00 Low
$495.00 High
| Metric | Value |
|---|---|
| Current Price | $470.70 |
| Target Low | $329.00 |
| Target Mean | $442.83 |
| Target Median | $456.00 |
| Target High | $495.00 |
| # Analysts | 12 |
| Recommendation | Sell (2.62) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$3.96 | $3.71 | $4.11 | 27.8% | -3.0% | 3↑ 5↓ | $0.7B | 14.4% | 8 |
| Next Q 2026-09-30 |
$4.26 | $4.06 | $4.43 | 10.3% | -5.2% | 0↑ 8↓ | $0.7B | 4.0% | 8 |
| Current FY 2026-12-31 |
$17.06 | $16.70 | $17.78 | 11.7% | +0.0% | 4↑ 6↓ | $2.8B | 9.5% | 10 |
| Next FY 2027-12-31 |
$18.56 | $17.85 | $19.26 | 8.8% | +0.0% | 3↑ 7↓ | $2.9B | 4.7% | 10 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $3.963 | |
| 7d ago | $4.090 | -0.127 |
| 30d ago | $4.085 | -0.122 |
| 60d ago | $4.083 | -0.120 |
| 90d ago | $3.840 | +0.123 |
8 analyst firms have rated this stock: 3 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 24, 2026 | Barclays | MAINTAIN | Equal-Weight | Equal-Weight |
| Apr 24, 2026 | BMO Capital | MAINTAIN | Market Perform | Market Perform |
| Apr 24, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Apr 24, 2026 | Baird | MAINTAIN | Outperform | Outperform |
| Mar 6, 2026 | Barclays | UPGRADE | Underweight | Equal-Weight |
| Mar 3, 2026 | RBC Capital | INITIATE | — | Outperform |
| Feb 18, 2026 | TD Cowen | UPGRADE | Sell | Hold |
| Feb 13, 2026 | Jefferies | UPGRADE | Hold | Buy |
| Feb 11, 2026 | Barclays | MAINTAIN | Underweight | Underweight |
| Feb 11, 2026 | Truist Securities | MAINTAIN | Hold | Hold |
| Feb 11, 2026 | Leerink Partners | MAINTAIN | Market Perform | Market Perform |
| Dec 15, 2025 | Barclays | MAINTAIN | Underweight | Underweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 5 | 10 | 1 | 0 | 45% | |
| May 1, 2026 | 4 | 5 | 10 | 1 | 0 | 45% | |
| Apr 1, 2026 | 4 | 5 | 10 | 1 | 0 | 45% | |
| Mar 1, 2026 | 4 | 4 | 9 | 2 | 0 | 42% | |
| Feb 1, 2026 | 0 | 1 | 11 | 4 | 2 | 6% | |
| Jan 1, 2026 | 0 | 1 | 11 | 4 | 2 | 6% |
Strong BuyBuyHoldSellStrong Sell
2 members of Congress traded this stock: 3 buys, 1 sells.
Congressional Trades
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| May 15, 2026 | David Taylor | R | HOUSE | BUY | $1,001 - $15,000 | Medpace Holdings Inc | May 29, 2026 (15d) |
| May 15, 2026 | David Taylor | R | HOUSE | BUY | $1,001 - $15,000 | Medpace Holdings Inc | May 29, 2026 (15d) |
| Feb 26, 2026 | David Taylor | R | HOUSE | BUY | $1,001 - $15,000 | Medpace Holdings Inc | Mar 9, 2026 (12d) |
| Jan 15, 2026 | Gilbert Cisneros | D | HOUSE | SELL | $15,001 - $50,000 | Medpace Holdings Inc | Feb 16, 2026 (33d) |
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 23, 2026
Clinical Trial
Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
Phase Phase 3 — COMPLETED
May 18, 2026
dark_pool
Dark Pool: MEDP — 0.6M shares, 27,512 trades
Week starting 2026-05-18. Total ATS volume: 553,061 shares across 27,512 trades.
May 11, 2026
dark_pool
Dark Pool: MEDP — 0.5M shares, 25,163 trades
Week starting 2026-05-11. Total ATS volume: 544,733 shares across 25,163 trades.
May 4, 2026
dark_pool
Dark Pool: MEDP — 0.5M shares, 28,032 trades
Week starting 2026-05-04. Total ATS volume: 549,783 shares across 28,032 trades.
Apr 29, 2026
short_interest
FTD: MEDP — 2,466 shares ($1.0M) failed to deliver
Settlement: 20260429, Price: $409.65, FTD Value: $1,010,196.9, MEDPACE HLDGS INC COM
Apr 27, 2026
dark_pool
Dark Pool: MEDP — 0.7M shares, 29,451 trades
Week starting 2026-04-27. Total ATS volume: 688,446 shares across 29,451 trades.
Apr 23, 2026
short_volume
Short Volume: MEDP — 72.0% short (0.5M / 0.7M)
Short: 530,634 | Exempt: 18,176 | TRF Vol: 736,516 | Short Ratio: 72.0% | Off-exchange volume (dark pool + OTC)
Apr 22, 2026
earnings_calendar
MEDP Q1 2026 Earnings After Market Close — 2026-04-22
Apr 20, 2026
dark_pool
Dark Pool: MEDP — 1.2M shares, 35,386 trades
Week starting 2026-04-20. Total ATS volume: 1,204,732 shares across 35,386 trades.
Apr 13, 2026
dark_pool
Dark Pool: MEDP — 0.7M shares, 25,219 trades
Week starting 2026-04-13. Total ATS volume: 699,606 shares across 25,219 trades.
Apr 6, 2026
dark_pool
Dark Pool: MEDP — 0.5M shares, 21,210 trades
Week starting 2026-04-06. Total ATS volume: 469,290 shares across 21,210 trades.
Mar 30, 2026
dark_pool
Dark Pool: MEDP — 0.2M shares, 14,534 trades
Week starting 2026-03-30. Total ATS volume: 241,220 shares across 14,534 trades.
Mar 23, 2026
dark_pool
Dark Pool: MEDP — 0.4M shares, 17,978 trades
Week starting 2026-03-23. Total ATS volume: 388,542 shares across 17,978 trades.
Mar 16, 2026
dark_pool
Dark Pool: MEDP — 0.4M shares, 19,823 trades
Week starting 2026-03-16. Total ATS volume: 398,651 shares across 19,823 trades.
Mar 9, 2026
dark_pool
Dark Pool: MEDP — 0.5M shares, 24,264 trades
Week starting 2026-03-09. Total ATS volume: 516,510 shares across 24,264 trades.
Mar 2, 2026
dark_pool
Dark Pool: MEDP — 0.5M shares, 22,654 trades
Week starting 2026-03-02. Total ATS volume: 479,187 shares across 22,654 trades.
Dec 4, 2025
Enforcement
Medpace, Inc. v. Agenus Inc. et al.
Court ruling from District Court, S.D. New York. Docket: 1:25-cv-04179